{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:08:08Z","timestamp":1788433688732,"version":"build-2803163510"},"reference-count":21,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P&amp;lt; .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P&amp;lt; .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P&amp;lt; .001]; median OS, 136.1 vs 75.3 months [P&amp;lt; .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018527","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:57:49Z","timestamp":1765486669000},"page":"1372-1380","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6536-1291","authenticated-orcid":false,"given":"Steven R.","family":"Hwang","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"3Center for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laveniya","family":"Kugathasan","sequence":"additional","affiliation":[{"name":"3Center for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1381-5810","authenticated-orcid":false,"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"4Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-5666","authenticated-orcid":false,"given":"Ashlee","family":"Joseph","sequence":"additional","affiliation":[{"name":"4Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4352-9296","authenticated-orcid":false,"given":"Taylor R.","family":"Brooks","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Hill","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David A.","family":"Bond","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran A.","family":"Nizamuddin","sequence":"additional","affiliation":[{"name":"7Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"7Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[{"name":"8Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Argao","sequence":"additional","affiliation":[{"name":"8Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[{"name":"9Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1943","authenticated-orcid":false,"given":"Christine E.","family":"Ryan","sequence":"additional","affiliation":[{"name":"10Division of Lymphoma, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid W.","family":"Merryman","sequence":"additional","affiliation":[{"name":"10Division of Lymphoma, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazneen B.","family":"Khan","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Ouchveridze","sequence":"additional","affiliation":[{"name":"12Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-2354","authenticated-orcid":false,"given":"Aung M.","family":"Tun","sequence":"additional","affiliation":[{"name":"12Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarish","family":"Ayyappan","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-4517","authenticated-orcid":false,"given":"Eric","family":"Mou","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Oncology, and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios N.","family":"Pongas","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoey I.","family":"Harris","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier L.","family":"Munoz","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Young","sequence":"additional","affiliation":[{"name":"16Division of Hematology & Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Portell","sequence":"additional","affiliation":[{"name":"16Division of Hematology & Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Baidoun","sequence":"additional","affiliation":[{"name":"17Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8582-1219","authenticated-orcid":false,"given":"Muhamad","family":"Alhaj Moustafa","sequence":"additional","affiliation":[{"name":"17Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Reagan","sequence":"additional","affiliation":[{"name":"18Division of Hematology & Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren G.","family":"Banaszak","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-9540","authenticated-orcid":false,"given":"Priyanka A.","family":"Pophali","sequence":"additional","affiliation":[{"name":"19Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Velayati","sequence":"additional","affiliation":[{"name":"20Division of Hematology & Oncology, Department of Medicine, Medical University of South Carolina College of Medicine, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Brian","family":"Greenwell","sequence":"additional","affiliation":[{"name":"20Division of Hematology & Oncology, Department of Medicine, Medical University of South Carolina College of Medicine, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2654-6269","authenticated-orcid":false,"given":"Drew","family":"Gerber","sequence":"additional","affiliation":[{"name":"21Division of Hematology, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[{"name":"22Division of Lymphoma & Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"22Division of Lymphoma & Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-0533","authenticated-orcid":false,"given":"Mayur S.","family":"Narkhede","sequence":"additional","affiliation":[{"name":"23Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-4207","authenticated-orcid":false,"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"23Division of Hematology and Oncology, Department of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-4619","authenticated-orcid":false,"given":"Anthony C.","family":"Stack","sequence":"additional","affiliation":[{"name":"24Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus R.","family":"Messmer","sequence":"additional","affiliation":[{"name":"24Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-7393","authenticated-orcid":false,"given":"Rahul S.","family":"Bhansali","sequence":"additional","affiliation":[{"name":"25Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"25Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara K.","family":"Moyo","sequence":"additional","affiliation":[{"name":"26Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"26Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-152X","authenticated-orcid":false,"given":"Manali K.","family":"Kamdar","sequence":"additional","affiliation":[{"name":"27Division of Hematology, Department of Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Anna","sequence":"additional","affiliation":[{"name":"27Division of Hematology, Department of Medicine, University of Colorado Anschutz School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-2212","authenticated-orcid":false,"given":"Alexander V.","family":"Stanisic","sequence":"additional","affiliation":[{"name":"28Division of Hematology & Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"28Division of Hematology & Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-178X","authenticated-orcid":false,"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-6481","authenticated-orcid":false,"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"21Division of Hematology, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"9Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"5","key":"2026022411381355600_bib1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"2026022411381355600_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"13","key":"2026022411381355600_bib3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2026022411381355600_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.23.01586","article-title":"Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study","volume":"42","author":"Sarkozy","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026022411381355600_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2026022411381355600_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9873","key":"2026022411381355600_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"2026022411381355600_bib8","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2026022411381355600_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2026022411381355600_bib10","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial)","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026022411381355600_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1200\/JCO.21.02698","article-title":"Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026022411381355600_bib12","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3324\/haematol.2022.282252","article-title":"Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis","volume":"108","author":"Di","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026022411381355600_bib13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2019-129404","article-title":"Maintenance rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with bendamustine + rituximab without autologous transplant","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2026022411381355600_bib14","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/bloodadvances.2020002068","article-title":"Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma","volume":"4","author":"Villa","year":"2020","journal-title":"Blood Adv"},{"issue":"26","key":"2026022411381355600_bib15","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"2026022411381355600_bib16","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2026022411381355600_bib17","doi-asserted-by":"crossref","first-page":"TPS8071","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8071","article-title":"Trial in progress: a phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL)","volume":"38","author":"Dreyling","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026022411381355600_bib18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411381355600_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2024-199710","article-title":"Ibrutinib-rituximab is superior to rituximab-chemotherapy in previously untreated older mantle cell lymphoma patients: results from the international randomised controlled trial, enrich","volume":"144","author":"Lewis","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411381355600_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood-2023-182374","article-title":"Primary analysis and results of bendamustine, rituximab, and venetoclax (BR-VEN) for initial treatment of mantle cell lymphoma in subjects over 60 years of age (PrE0405)","volume":"142","author":"Portell","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026022411381355600_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2020-140457","article-title":"Predictive power of early, sequential MRD monitoring in peripheral blood and bone marrow in patients with mantle cell lymphoma following autologous stem cell transplantation with or without rituximab maintenance; final results from the LyMa-MRD project, conducted on behalf of the Lysa Group","volume":"136","author":"Callanan","year":"2020","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1372\/2504317\/blooda_adv-2025-018527-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1372\/2504317\/blooda_adv-2025-018527-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:38:21Z","timestamp":1771951101000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1372\/557282\/Benefit-of-rituximab-maintenance-after-first-line"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018527","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,17]]}}}